Integrated Advisors Network LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 141.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,002 shares of the medical research company's stock after acquiring an additional 7,030 shares during the quarter. Integrated Advisors Network LLC's holdings in IQVIA were worth $2,777,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. AdvisorNet Financial Inc raised its position in shares of IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company's stock valued at $29,000 after buying an additional 95 shares during the last quarter. BKM Wealth Management LLC acquired a new position in IQVIA in the 4th quarter valued at approximately $32,000. Activest Wealth Management bought a new stake in shares of IQVIA in the 4th quarter worth approximately $35,000. Security National Bank bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $41,000. Finally, CVA Family Office LLC acquired a new position in shares of IQVIA in the fourth quarter valued at $43,000. Institutional investors and hedge funds own 89.62% of the company's stock.
IQVIA Trading Down 0.6 %
Shares of NYSE IQV traded down $1.21 during mid-day trading on Friday, hitting $212.75. The company's stock had a trading volume of 845,033 shares, compared to its average volume of 1,199,631. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The stock has a market cap of $38.76 billion, a price-to-earnings ratio of 29.06, a price-to-earnings-growth ratio of 1.95 and a beta of 1.53. The company's fifty day simple moving average is $228.15 and its 200-day simple moving average is $230.32. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73.
IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping analysts' consensus estimates of $2.19 by $0.11. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on IQV shares. SVB Leerink assumed coverage on shares of IQVIA in a report on Monday, February 26th. They issued an "outperform" rating and a $290.00 price target on the stock. StockNews.com upgraded IQVIA from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Evercore ISI dropped their price objective on IQVIA from $275.00 to $250.00 and set an "outperform" rating for the company in a research note on Friday, May 3rd. Robert W. Baird lowered their target price on shares of IQVIA from $254.00 to $245.00 and set a "neutral" rating on the stock in a report on Friday, May 3rd. Finally, Truist Financial cut their price target on shares of IQVIA from $297.00 to $292.00 and set a "buy" rating for the company in a report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $258.40.
Get Our Latest Stock Analysis on IQV
IQVIA Company Profile
(Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
- Five stocks we like better than IQVIA
- What is a Dividend King?
- MarketBeat Week in Review – 6/10 - 6/14
- What is Forex and How Does it Work?
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- How to Calculate Options Profits
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
→ Low Risk $5,000 - $10,000 Per Year For Life Investing Strategy (From Augury Research) (Ad)
Should you invest $1,000 in IQVIA right now?
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
20 High-Yield Dividend Stocks that Could Ruin Your Retirement
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
